CM
JNCE

Crestline Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Crestline Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-13,212
Closed -$295K – 298
2018
Q1 		$295K Buy
+13,212
New +$293K 0.04% 204

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crestline Management's JNCE Position: Q2 2018 in Review

Crestline Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 13,212 shares — an estimated $295K sold.

Crestline Management first reported a position in JNCE in Q1 2018 and held it in 1 quarter. The position peaked at $295K in Q1 2018. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • Crestline Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 13,212 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $295K.
  • Crestline Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Crestline Management's Jounce Therapeutics, Inc. Common Stock position peaked at $295K in Q1 2018.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.